Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2011 Jan 9;17(3):309–318. doi: 10.1016/j.bbmt.2010.12.710

Fig. 3. The potency of Ag-specific and polyclonal iTregs in suppressing GVHD.

Fig. 3

A and B, OVA+ (B6 × bm12)F1 mice were lethally irradiated and transferred with TCD-BM alone or plus 1.6 × 106 CD4+CD25− T cells (Teffs alone) from B6 donors. OVA-specific iTregs (CD4+CD25+GFP+) were generated from OT-II T cells and were added at 0.2 or 0.4 × 106 each into donor graft. C and D, OVA− (B6 × bm12)F1 mice were lethally irradiated and transferred with TCD-BM alone or plus 1 × 106 CD4+CD25− T cells (Teffs alone) from B6 donors. Polyclonal iTregs (CD4+CD25+GFP+) generated from WT B6 T cells with anti-CD3 stimulation plus TGFβ were added at 0.25 or 0.5 × 106 each into donor graft. Recipient survival (A and C) and body weight changes (B and D) are shown. Five or six recipients were included in each group for both experiments.